Peter Altman, President and CEO of BioCardia, Inc., filed a Form 4 on October 20, 2026, disclosing two open-market purchases of BioCardia common stock totaling 500 shares made on October 15 and October 16, 2026.

Key Highlights

  • Reporting person: Peter Altman, Director and President and CEO of BioCardia, Inc. (NASDAQ:BCDA)
  • First purchase: 200 shares acquired on October 15, 2026, at a weighted average price of $0.95 per share, with individual trades ranging from $0.94 to $0.95
  • Second purchase: 300 shares acquired on October 16, 2026, at a weighted average price of $0.95 per share, with individual trades ranging from $0.94 to $0.96
  • Total shares after transactions: 385,385 shares of common stock held directly following the two reported purchases
  • Transaction code: Both transactions are coded "P" (open-market purchase) with no derivative securities involved

Altman's October 2026 Open-Market Purchases of BioCardia Common Stock

According to the filing, Peter Altman, who serves as both a Director and President and CEO of BioCardia, Inc., purchased BioCardia common stock on two consecutive trading days in October 2026. The first transaction, dated October 15, 2026, involved the acquisition of 200 shares at a weighted average price of $0.95 per share. The filing notes that this transaction was executed in multiple trades ranging from $0.94 to $0.95 per share, and that the reported price reflects the weighted average. Following that purchase, Altman's direct beneficial ownership stood at 385,085 shares.

The second transaction, dated October 16, 2026, involved the acquisition of 300 shares at a weighted average price of $0.95 per share. The filing states that this transaction was also executed in multiple trades, with per-share prices ranging from $0.94 to $0.96. After this purchase, Altman's directly held beneficial ownership increased to 385,385 shares of BioCardia common stock. Both transactions are classified under transaction code "P," indicating open-market purchases. No derivative securities were reported in Table II of the filing.

The filing further discloses that Altman "undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price" for both transactions. The Form 4 was signed by Peter Altman and filed on October 20, 2026. No Rule 10b5-1 plan checkbox was indicated as checked in the filing.

What Was Disclosed

BioCardia's President and CEO Peter Altman reported two open-market purchases of BioCardia common stock totaling 500 shares on October 15 and 16, 2026, both at a weighted average price of $0.95 per share, bringing his direct holdings to 385,385 shares.